Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paul G. Wannamaker
Observed names:
PG Wannamaker,
Paul G Wannamaker,
Paul Wannamaker
Observed institutions:
GlaxoSmithKline (United Kingdom),
ViiV Healthcare (United Kingdom),
GlaxoSmithKline (United States),
Saint Michael's Medical Center
OpenAlex ID:
A5061912045
High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients
2008
·
Michael Saag
, Rukmini Balu
, et al.
·
Clinical Infectious Diseases
·
425
PDF
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
2006
·
Joseph Eron
, Patrick Yeni
, et al.
·
The Lancet
·
339
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
2009
·
Kimberly Y Smith
, Parul Patel
, et al.
·
AIDS
·
219
The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients
2003
·
Amalia Rodriguez-French
, Jack Boghossian
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
149
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America
2008
·
Benjamin Young
, Kathleen Squires
, et al.
·
AIDS
·
94
A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity
2006
·
PN Kumar
, A Rodriguez‐French
, et al.
·
HIV Medicine
·
67
PDF
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
2010
·
Kathleen E Squires
, Benjamin Young
, et al.
·
AIDS
·
65
Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges
2026
·
Aadia I. Rana
, Lu Zheng
, et al.
·
New England Journal of Medicine
·
41
Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients
2010
·
Kathleen E. Squires
, Benjamin Young
, et al.
·
HIV Clinical Trials
·
25
Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)
2013
·
David A Margolis
, Joseph J Eron
, et al.
·
Antiviral Therapy
·
14
PDF
High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR)
2007
·
Michael S. Saag
, Ramani Balu
, et al.
·
Murdoch University Research Portal
·
14
PDF
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
2025
·
Babafemi O Taiwo
, Yu Zheng
, et al.
·
Clinical Infectious Diseases
·
5
PDF
A Study of HIV Provider Attitudes Toward HLA-B*5701 Testing in the United States
2009
·
Maria E. Watson
, Lisa G. Patel
, et al.
·
AIDS Patient Care and STDs
·
5
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
2025
·
Peter A Leone
, Alejandro Ferro
, et al.
·
The Journal of Infectious Diseases
·
4
PDF
Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial
2010
·
Calvin Cohen
, Edwin DeJesus
, et al.
·
HIV Clinical Trials
·
4
PDF
VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results
2025
·
Peter A. Leone
, Jan Losos
, et al.
·
Antimicrobial Agents and Chemotherapy
·
2
PDF
1034. Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Interim Results from the CUSTOMIZE study
2020
·
Cindy Garris
, Ronald D’Amico
, et al.
·
Open Forum Infectious Diseases
·
1
1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE)
2020
·
Maggie Czarnogorski
, Cindy Garris
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial
2003
·
For the ESS40005 Study Team
, Margaret A. Fischl
, et al.
·
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
·
1
P-380. The Clinical Development of VH3810109 (N6LS): Advancing Ultra-Long-Acting HIV Treatment into the Future
2026
·
Peter Leone
, Paul Wannamaker
, et al.
·
Open Forum Infectious Diseases
HLA-B*5701 screening reduces abacavir hypersensitivity reactions (ABC HSR): Multiple lines of evidence to establish a new standard of care
2008
·
Paul Wannamaker
, S. Mallal
, et al.
·
Murdoch University Research Portal
Show more works
View as search
Works count:
21
Citation count:
1,475
H-index:
11
I10-index:
11
Year
Topic
Type
